ritanserin has been researched along with Dementia Praecox in 17 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was designed to investigate the effect of ritanserin added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double blind and randomized clinical trial." | 9.13 | Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Ghoreishi, A; Malek-Hosseini, M; Raznahan, M; Rezazadeh, SA, 2008) |
| "Twenty-two male inpatients who met DSM-III-R criteria for schizophrenia or schizoaffective disorder completed 4 test days during which 10 mg ritanserin or matched placebo was administered orally 50 min prior to the intravenous infusion of 0." | 9.10 | Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. ( Abi-Dargham, A; Abi-Saab, W; Charney, DS; D'Souza, DC; Erdos, JP; Gueorgueva, R; Heninger, GR; Karper, LP; Krystal, JH; Rajhans, S; Seibyl, JP; Wong, ML, 2002) |
| "The effect of the selective serotonin-2 antagonist ritanserin was investigated in an open study of patients with schizophrenia." | 9.07 | An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. ( Eriksson, B; Farde, L; Nordström, AL; Wiesel, FA, 1994) |
| "The effectiveness of ritanserin, a selective 5-HT2 and 5-HT1c antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial." | 9.07 | Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. ( Boom, AJ; Botter, PA; Busard, HL; Duinkerke, SJ; Jansen, AA; van Dongen, PA; van Haaften, AJ; van Laarhoven, JH, 1993) |
| " This study was designed to investigate the effect of ritanserin added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double blind and randomized clinical trial." | 5.13 | Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Ghoreishi, A; Malek-Hosseini, M; Raznahan, M; Rezazadeh, SA, 2008) |
| "Twenty-two male inpatients who met DSM-III-R criteria for schizophrenia or schizoaffective disorder completed 4 test days during which 10 mg ritanserin or matched placebo was administered orally 50 min prior to the intravenous infusion of 0." | 5.10 | Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. ( Abi-Dargham, A; Abi-Saab, W; Charney, DS; D'Souza, DC; Erdos, JP; Gueorgueva, R; Heninger, GR; Karper, LP; Krystal, JH; Rajhans, S; Seibyl, JP; Wong, ML, 2002) |
| "The effect of the selective serotonin-2 antagonist ritanserin was investigated in an open study of patients with schizophrenia." | 5.07 | An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. ( Eriksson, B; Farde, L; Nordström, AL; Wiesel, FA, 1994) |
| "The effectiveness of ritanserin, a selective 5-HT2 and 5-HT1c antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial." | 5.07 | Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. ( Boom, AJ; Botter, PA; Busard, HL; Duinkerke, SJ; Jansen, AA; van Dongen, PA; van Haaften, AJ; van Laarhoven, JH, 1993) |
| "To clarify the implication of antagonism of serotonin (5-HT)2 receptors in the treatment of schizophrenia, the effects of ritanserin (RIT) on the development of reverse tolerance in rats repeatedly administered methamphetamine (MAP) were investigated and compared with those of low doses of haloperidol (HPD)." | 3.70 | Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in methamphetamine-sensitized rat. ( Ishigooka, J; Miura, S; Nagata, E; Tanaka, T; Watanabe, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 11 (64.71) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, Y | 1 |
| McCorvy, JD | 1 |
| Harpsøe, K | 1 |
| Lansu, K | 1 |
| Yuan, S | 1 |
| Popov, P | 1 |
| Qu, L | 1 |
| Pu, M | 1 |
| Che, T | 1 |
| Nikolajsen, LF | 1 |
| Huang, XP | 1 |
| Wu, Y | 1 |
| Shen, L | 1 |
| Bjørn-Yoshimoto, WE | 1 |
| Ding, K | 1 |
| Wacker, D | 1 |
| Han, GW | 1 |
| Cheng, J | 1 |
| Katritch, V | 1 |
| Jensen, AA | 1 |
| Hanson, MA | 1 |
| Zhao, S | 1 |
| Gloriam, DE | 1 |
| Roth, BL | 1 |
| Stevens, RC | 1 |
| Liu, ZJ | 1 |
| Akhondzadeh, S | 1 |
| Malek-Hosseini, M | 1 |
| Ghoreishi, A | 1 |
| Raznahan, M | 1 |
| Rezazadeh, SA | 1 |
| Lindström, E | 1 |
| von Knorring, L | 1 |
| Jahnová, E | 1 |
| Kitaichi, K | 1 |
| Yamada, K | 1 |
| Hasegawa, T | 1 |
| Furukawa, H | 1 |
| Nabeshima, T | 1 |
| Wiesel, FA | 1 |
| Nordström, AL | 1 |
| Farde, L | 1 |
| Eriksson, B | 1 |
| Duinkerke, SJ | 1 |
| Botter, PA | 1 |
| Jansen, AA | 1 |
| van Dongen, PA | 1 |
| van Haaften, AJ | 1 |
| Boom, AJ | 1 |
| van Laarhoven, JH | 1 |
| Busard, HL | 1 |
| Bailey, P | 1 |
| Duval, F | 1 |
| Macher, JP | 1 |
| Martin, P | 1 |
| Waters, N | 1 |
| Carlsson, A | 1 |
| Carlsson, ML | 1 |
| Tanaka, T | 1 |
| Ishigooka, J | 1 |
| Watanabe, S | 1 |
| Nagata, E | 1 |
| Miura, S | 1 |
| Abi-Saab, W | 1 |
| Seibyl, JP | 1 |
| D'Souza, DC | 1 |
| Karper, LP | 1 |
| Gueorgueva, R | 1 |
| Abi-Dargham, A | 1 |
| Wong, ML | 1 |
| Rajhans, S | 1 |
| Erdos, JP | 1 |
| Heninger, GR | 1 |
| Charney, DS | 1 |
| Krystal, JH | 1 |
| Miller, CH | 1 |
| Hummer, M | 1 |
| Pycha, R | 1 |
| Fleischhacker, WW | 1 |
| Strauss, WH | 1 |
| Klieser, E | 1 |
| Gelders, YG | 1 |
| Vinar, O | 1 |
| Molcan, J | 1 |
| Náhunek, K | 1 |
| Svestka, J | 1 |
| Zapletálek, M | 1 |
| Janssen, PA | 1 |
7 trials available for ritanserin and Dementia Praecox
| Article | Year |
|---|---|
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Co | 2008 |
Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations.
Topics: Adult; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; | 1994 |
An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Biogenic Monoamines; Hemodynamics; Humans; Male; Prolact | 1994 |
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
Topics: Antipsychotic Agents; Basal Ganglia; Double-Blind Method; Drug Therapy, Combination; Facial Expressi | 1993 |
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
Topics: Adult; Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Humans; Male; Middle Aged; Pip | 2002 |
Thymosthenic agents, a novel approach in the treatment of schizophrenia.
Topics: Brain; Butyrophenones; Humans; Isoxazoles; Piperidines; Pyrimidinones; Randomized Controlled Trials | 1989 |
Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?
Topics: Clinical Trials as Topic; Depressive Disorder; Humans; Piperidines; Ritanserin; Schizophrenia; Serot | 1987 |
10 other studies available for ritanserin and Dementia Praecox
| Article | Year |
|---|---|
5-HT
Topics: Ergotamine; HEK293 Cells; Humans; Obesity; Protein Domains; Receptor, Serotonin, 5-HT2C; Ritanserin; | 2018 |
The effect of risperidone and ritanserin on human IgG and IgM synthesis in vitro.
Topics: Antipsychotic Agents; B-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Im | 1994 |
Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 1994 |
Treating negative symptoms.
Topics: Antipsychotic Agents; Depression; Drug Therapy, Combination; Humans; Psychiatric Status Rating Scale | 1994 |
[Risperdal: a new hope for schizophrenic patients?].
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Humans; Ritanserin; Schizophrenia; Serotonin Ant | 1994 |
The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).
Topics: Animals; Antipsychotic Agents; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Fluorobenzene | 1997 |
Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in methamphetamine-sensitized rat.
Topics: Animals; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Drug Tolerance; Haloperidol; Loc | 1998 |
The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Male; Psycho | 1992 |
Psychotropic effects of ritanserin, a selective S2 antagonist: an open study.
Topics: Adult; Depression; Electrocardiography; Female; Humans; Male; Psychiatric Status Rating Scales; Psyc | 1991 |
Ritanserin in schizophrenic patients.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Humans; Middle Aged; Piperidines; Ritanserin; Schizop | 1989 |